Biotech M&A Q1 2026
Q1 wrap of biotech/biopharma company-level control transactions announced in 2026 — target, acquirer, deal value, structure, premium, and a one-line “why it matters.”
Latest 2026 M&A deals here →
2026 M&A Tracker
Last updated: 22 Apr 2026
2026 biotech M&A market snapshot
- 16 transactions are included in this Q1 2026 wrap across public and private biotech/biopharma targets.
- Total disclosed headline value across the quarter reached roughly US$44B, with activity accelerating sharply into March.
- Largest Q1 deals were Arcellx / Gilead at roughly US$7.8B implied equity value and Centessa / Lilly at up to US$7.8B.
- Pace by month skewed heavily to quarter-end: roughly US$4.6B in January, US$11.2B in February, and US$28.3B in March, implying roughly US$44.1B of disclosed headline value across Q1, with eight of 16 transactions landing in March alone.
- The tape still looked selective rather than indiscriminate: buyers paid for approved products, near-commercial assets, or clear strategic platform fit rather than broad early-stage optionality alone.
March 2026
Apellis Pharmaceuticals
31-Mar-2026
Acquirer: Biogen
Total deal value: Approximately US$5.6B
|
Upfront: US$41.00/share in cash
Structure: All-cash acquisition + up to US$4.00/share in CVRs tied to SYFOVRE sales milestones
|
Type: Public
|
1D Premium: ~140% to prior close
Therapeutic area: Immunology / Rare disease / Ophthalmology / Nephrology
|
Stage / lead assets: EMPAVELI (pegcetacoplan), approved in PNH and C3G / primary IC-MPGN; SYFOVRE (pegcetacoplan), approved in geographic atrophy
Why it matters: Biogen is buying immediate commercial revenue plus a broader complement platform at a time when it needs new growth vectors beyond legacy MS. Strategically, the deal adds approved rare-disease and retinal assets today while also giving Biogen a more credible foothold in nephrology ahead of its broader immunology build-out.
Centessa Pharmaceuticals
31-Mar-2026
Acquirer: Eli Lilly
Total deal value: Up to US$7.8B
|
Upfront: US$38.00/share in cash
Structure: All-cash acquisition + one CVR worth about US$9.00/share
|
Type: Public
|
1D Premium: ~37.8% to prior close
Therapeutic area: Neuroscience / Sleep medicine
|
Stage / lead assets: Cleminorexton (formerly ORX750), a Phase 2 OX2R agonist for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia
Why it matters: Lilly is paying up to secure a clinically de-risking orexin agonist platform and enter sleep medicine with a potential best-in-class wakefulness asset. The read-through is that large-cap buyers are willing to underwrite differentiated neuroscience mechanisms when there is a clear biology, sizable commercial white space, and room to build a broader franchise around the lead program.